IL17A and psoriasis: In this pilot study, we assessed the effects of anti-IL-17 and anti-IL-23 monoclonal antibodies on systemic biomarkers of dysbiosis (TMAO) and OxS (oxLDL, d-ROMs), alongside an analysis of lipid profile and adipokine levels in patients with moderate-to-severe psoriasis.